Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Pfizer Declares First-Quarter 2024 Dividend

December 14, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Completes Acquisition of Seagen

December 14, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Provides Full-Year 2024 Guidance

December 13, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

December 12, 2023

From Pfizer Inc.

Via Business Wire

FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B

December 11, 2023

From Pfizer Inc.

Via Business Wire

Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

December 09, 2023

From Pfizer Inc.

Via Business Wire

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

December 08, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

December 01, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

November 21, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

November 02, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

November 02, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Reports Third-Quarter 2023 Results

October 31, 2023

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

October 26, 2023

From Pfizer Inc.

Via Business Wire

FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

October 20, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance

October 13, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

October 13, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

October 12, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases

October 05, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Declares Fourth-Quarter 2023 Dividend

October 04, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

September 22, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

September 19, 2023

From Pfizer Inc.

Via Business Wire

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

September 19, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts

September 18, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

September 12, 2023

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

September 11, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

September 05, 2023

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

August 30, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences

August 30, 2023

From Pfizer Inc.

Via Business Wire

European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV

August 24, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

August 21, 2023

From Pfizer Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.